BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders
BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - April 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging that the Company violated federal securities laws.
紐約，紐約-(Newsfile Corp.-2021年4月9日)-克萊恩律師事務所(Klein Law)宣佈，已代表股東提起集體訴訟藍鳥生物股份有限公司(Bluebird Bio，Inc.)(納斯達克市場代碼：BLUL)指控該公司違反了聯邦證券法。
Class Period:May 11, 2020andNovember 4, 2020
上課時間：2020年5月11日和2020年11月4日
Lead Plaintiff Deadline:April 13, 2021
首席原告截止日期：2021年4月13日
Learn more about your recoverable losses in BLUE:
以藍色瞭解有關您的可挽回損失的更多信息：
http://www.kleinstocklaw.com/pslra-1/bluebird-bio-inc-loss-submission-form?id=14551&from=5
Http://www.kleinstocklaw.com/pslra-1/bluebird-bio-inc-loss-submission-form?id=14551&from=5
The filed complaint alleges that bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
起訴書稱，藍鳥生物公司做出了重大虛假和/或誤導性陳述和/或未能披露：(1)支持藍鳥公司提交用於SCD的LentiGlobin的BLA的數據不足以證明藥品的可比性；(2)被告淡化了與新冠肺炎大流行有關的幹擾對該公司提交用於SCD的LentiGlobin的BLA時間表的可預見影響，特別是在製造方面；(3)由於上述所有情況，這是可以預見的。及(Iv)因此，本公司的公開陳述在所有相關時間均屬重大虛假及誤導性陳述。
Shareholders have until April 13, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
股東可以在2021年4月13日之前向法院請願，要求獲得主要原告地位。你分享任何賠償的能力並不需要你擔任主要原告。
For additional information about the BLUE lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.
有關藍色訴訟的更多信息，請聯繫Esq的J.Klein。請撥打212-616-4899或點擊上面的鏈接。
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
J·克萊因(J.Klein)，Esq.在全國範圍內代表投資者並參與涉及金融欺詐的證券訴訟。律師廣告。先前的結果不能保證類似的結果。
CONTACT:
聯繫方式：
J. Klein, Esq.
J·克萊因(J.Klein)，Esq.
Empire State Building
帝國大廈
350 Fifth Avenue
第五大道350號
59th Floor
59樓
New York, NY 10118
紐約，紐約，10118
jk@kleinstocklaw.com
郵箱：jk@kleinstocklaw.com
Telephone: (212) 616-4899
電話：(212)616-4899
Fax: (347) 558-9665
傳真：(347)558-9665
www.kleinstocklaw.com
Www.kleinstocklaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80026
要查看本新聞稿的源版本，請訪問https://www.newsfilecorp.com/release/80026
譯文內容由第三人軟體翻譯。